MedPage Today - AAN: Novel Drugs Ease Troubling PD Symptoms

New York, NY
 – March 18, 2013  –– 

An adenosine 2-alpha receptor antagonist called tozadenant reduced so-called "off time" without promoting dyskinesias, according to C. Warren Olanow, MD, of the Icahn School of Medicine at Mount Sinai in research presented at the American Academy of Neurology annual meeting. In the phase II trial conducted by Dr. Olanow and colleagues, 420 patients were randomized to placebo or one of four doses of tozadenant for 12 weeks in addition to stable doses of levodopa. All patients were showing at least 2.5 hours of off time—when the medication wears off—daily at enrollment. Tozadenant showed significant decreases in off time when measured at week 12. Learn more